Revvity, Inc.
RVTYHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframePart of the healthcare sector, Revvity, Inc. (RVTY) is listed under Diagnostics & Research. Valued at $11.20B, RVTY is a large-cap name in its sector. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Market Cap
$11.20B
Beta
1.05
P/E (TTM)
48.26
P/E (Fwd)
17.25
EPS (TTM)
$2.08
EPS (Fwd)
$5.82
ROE
3.2%
ROA
2.3%
Cash
$860.3M
Total Debt
$3.35B
Free CF
$509.0M
52W Change
8.6%
Annual Financials
Cash vs Debt
On the balance sheet, RVTY has $860.3M in cash with $3.35B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $509.0M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 3.2% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.3% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $3.31B to $2.86B.
Investors considering Revvity, Inc. should weigh the typical risks associated with RVTY's sector, size, and financial profile against their own risk tolerance and investment objectives. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Revvity, Inc.'s trajectory.